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In order to summarize and analyze the internal 
relations of tumor formation and metastasis to 
blood-stasis syndrome and the influential factors of 
blood-activating and stasis-resolving drugs (BASRD) 
on tumor inhibition and metastasis, and to grasp the 
opportunity of selecting and using BASRD, the 
authors have retrieved by the computer the relative 
literature published from 1985 to 2006 in Full-text 
Database of Chinese Periodicals with “BASRD” and 
“cancer” as retrieval words. The result has shown that 
the proportion of BASRD and the appropriate time of 
taking them should be carefully grasped in treating 
cancer with Chinese and Western drugs. Different 
dosage and potency of BASRD should be used for 
different syndromes and stages. At the early stage of 
interventional treatment, the use of drugs for 
replenishing qi and activating blood can not only 
enhance immunity and reduce metastatic rate of 
cancer but also increase long-term survival rate.  
After the focus has been stabilized, the combined use 
of strengthening the body resistance and eliminating 
pathogenic factors and the additional use of drugs for 
resolving masses and removing stasis can enhance 
the effective rate of treating  non-small cell lung 
cancer of late stage.  
Judging from research into molecular biology, most 
scholars hold that at the early stage of cancerous 
change, a series of genetic alterations damage the 
balance of cell growth, making it out of control.  
Most of protooncogenes are growth factor and its 
receptor necessary for the growth of normal cells.1
Their mutation, proliferation and rearrangement can 
lead to excessive growth of cells. Lack, loss, 
deactivation or variation of other genes can cause 
generation or development of tumor. Immun- 
odeficiency is also a prerequisite for generation and 
development of tumor. Oncogene, antioncogene and 
associated genes of apoptosis are often related to 
tumor.   
Tumor metastasis resulting from invasion by tumor 
cells and from effect of metastasis-related genes is a 
multi-step process of development. Firstly, the 
metastatic feature of tumor cells, decrease in 
adhesive force and increase in superficial charges 
make tumor cells separate from mother cells.  
Secondly, the motion of tumor cells, release of 
protein-solving enzyme and other factors strengthen 
their activity to penetrate basement membrane and 
destroy cellular matrix, making tumor cells infiltrate 
into peripheral tissue. Thirdly, potential invasion by 
tumor cells, adhesion to vascular and lymphangial 
basement membrane and the ability to evade being 
recognized by immune system make tumor cells 
invade vascular and lymphatic vessels and survive in 
circulatory system. Tumor cells adhere to the inner 
wall of new vascular and lymphatic vessels because 
of their adhesive factors, angiogenic factors and 
formation of micro-tumor. Due to changes in 
ingredients of the basement membrane of vascular 
and lymphangial endotheliocytes, tumor cells pierce 
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through the wall of vessels to form micro-metastatic 
focus. Angiogenic factors promote the growth of 
blood vessels and the expansion of metastatic focus.  
It is uneasy for tumor to go through a process from 
generation to metastasis. An article shows that for a 
1–1.8 g tumor, 1 g tumor can release (3.2±1.4) × 105
tumor cells into blood in 24 hours, but less than 
1/1000 of tumor cells can eventually survive and 
form metastatic tumor.2  
Blood-stasis Syndrome is Main Pathological 
Change in Generation and Metastasis of 
Malignant Tumor  
1. Malignant tumorigenesis resulting from 
blood-stasis syndrome 
TCM holds that malignant tumor is directly related to 
blood stasis. Its main pathological change is the 
concentrated reflection of blood stasis, toxin and 
deficiency in internal organs, channels and skin.  
Cancerous toxin, an endopathic cause, can induce 
blood stasis and deficiency. Blood stasis is caused by 
poor blood circulation. In observation of nail fold 
microcirculation in tumor patients, it is found that 
microcirculatory disturbance makes blood flow slow 
down.3 The obvious erythrocyte aggregation, 
exudation and hemorrhage are advantageous to the 
generation, development and metastasis of tumor.  
The stimulation by toxic substances of tumor cells 
can aggravate microcirculatory disturbance.    
In probing the relations of microcirculation 
disturbance to tumor formation and metastasis,4  
white micro-thrombus was found in blood circulation 
of 88% of patients and its quantity was correlated 
positively with the progress of the illness. Blood 
stasis is the main pathological cause of cancer such as 
gastric cancer. Researches by ZHOU A-gao (਼䰓催) 
and others have shown that 4 hypercoagulative 
indexes of patients with malignant tumor in stomach 
were significantly different from normal values.5
Antithrombin ċ, plasma fibronectin and fibrinolysis 
activity were significantly lower than normal values, 
indicating reduced anticoagulative and fibrinolytic
functions of tumor patients. Factor Đ relative antigen 
was significantly higher than normal value.  
Regressive analysis of relationship between clinical 
pathology and hypercoagulative indexes shows that 
the severer the illness is and the later the stage of 
disease is, the severer the hypercoagulative state in 
the patient of gastric cancer is.  
Most patients with liver cancer are clinically 
manifested as blood-stasis syndrome.  82.7% of 440 
cancer patients under hemorheologic observation 
were in different state of blood hyperviscosity with 
the order of cardiac cancer, liver cancer, lung cancer, 
thyroid cancer, nasopharyngeal carcinoma, oral 
cancer and gastric carcinoma.6 Plasma fibrinogen of 
liver cancer patients is also higher than that of 
patients with other hepatic diseases. In his research, 
WANG Yu-tang confirmed that 32.6% of 136 lung 
cancer patients presented thrombocytosis, and that 
the incidence was 39.3% in patients at ĉstage and 
32% at Č stage.7 Having detected 11 clotting indexes 
of 41 lung cancer patients, LI Guo-xian and 
othersindicated that 61% of the 41 lung cancer 
patients were in hypercoagulative state.8 The more 
malignant the cancer was and the later stage the 
patient was at, the more obvious the hypercoagulative 
state was.   
2. Development and metastasis of malignant tumor is 
continuation of blood-stasis syndrome 
Clinical research has confirmed that the development 
and metastasis of tumor accompanied by blood stasis 
syndrome were manifested as blood hyperviscosity 
and swelling of internal organs to press their 
peripheral tissues. Blood hyperviscosity can promote 
cancer metastasis, during which the hypercoagulant 
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state exists in microthrombosis in oncocytes, its 
adhesion to capillary endothelium and other 
metastatic links. As discovered in research into the 
hemorheology of 77 lung cancer patients, plasma 
viscosity and fibrinogen of patients with lung cancer 
transfer were much higher than those of patients 
without lung cancer transfer, indicating that 
hypercoagulant state of lung cancer patients was a 
main internal factor for lung cancer transfer, which 
was very closely related to blood-stasis syndrome in 
microcosmic.9 Hemorheological index of gastric 
cancer patients at various stage shows that the 
specific viscosity of whole blood and plasma in 
lymph node metastasis group, far-end metastasis 
group and no metastasis group were remarkably 
higher than those in healthy group. Having 
summarized a great number of articles, MA Wen-jian 
and others held that hypercoagulation might directly 
promote tumor metastasis and was closely related to 
blood-stasis syndrome in TCM.10 It can thus be 
believed that blood-stasis is an important factor for 
relapse and metastasis of cancer. 
BASRD can Relieve Hypercoagulation and 
Improve Inner Environment in Which Malignant 
Tumor Exists
1. BASRD is main medicine for treating relapse and 
metastasis of cancer 
BASRD are main medicine for eliminating cancer.  
Clinical pharmacology has confirmed that BASRD, 
such as E Zhu (㥾ᴃ Rhizoma Curcumae), Hu Zhang 
(㰢ᴪ Rhizoma Polygoni Cuspidati), Chuan Shan Jia 
(こቅ⬆ Squama Manitis) and Ling Xiao Hua (ޠ䳘
㢅 Flos Campsis), could relieve hypercoagulation by 
means of promoting fibrinolysis, inhibiting agg- 
regation of blood platelet, improving micro- 
circulation and lowering blood viscosity to make new 
capillaries in tumor metastatic focus degenerate and 
to enhance immunity recognition ability. Extract from 
Chi Shao (䌸㡡Radix Paeoniae Rubra) could prolong 
prothrombin time and obviously inhibit spontaneous 
metastasis in the mice with Lewis lung cancer and 
melanoma. Dan Shen ˄ Ѝ খ  Radix Salviae 
Miltiorrhizae), Tu Bie Chong (ೳ努㰿 Eupolyphaga 
seu Steleophaga), Tao Ren (ḗҕ Semen Persicae), 
Hong hua (㑶㢅 Flos Carthami), Chuan Xiong (Ꮁ㡢
Rhizoma Chuanxiong), Dang Gui (ᔧᔦ Radix 
Angelicae Sinensis) and Mu Dan Pi (⠵ЍⲂ Cortex 
Moutan) can lower TXB2 level in plasma and inhibit 
generation of TXA2 in tumor-bearing mice. They 
could exert an adverse effect on cancer metastasis by 
inhibiting adhesion of tumor cells to blood platelet 
and vascular wall. Ligustrazine injection can enhance 
activation of NK cells in animals and inhibit 
melanoma metastasis to lung. BASRD can inhibit 
tumor generation and metastasis through inducing 
apoptosis of tumor cells. Tanshinone prevents cells 
from entering S stage and inhibits DNA synthesis to 
induce apoptosis. Achyranthes bidentata poly- 
saccharides can induce generation of tumor necrosis 
factor ȕ in mice. Total glucosides of paeony have 
dual regulative effect on tumor necrosis factor 
produced by macrophage in abdominal cavity of rats.  
To sum up, blood-activating drugs can alter whole 
blood viscosity and ability of platelet aggregation to 
prevent cancer cells from penetrating vascular wall.11  
BASRD are main medicine for preventing and 
treating cancer relapse and metastasis. 39 patients 
with tumor of digestive tract were treated by 
chemotherapy combined with blood-activating and 
stasis-resolving therapy with a recipe consisting of 
Dan Shen (Ѝখ Radix Salviae Miltiorrhizae) 20g, 
Tao Ren (ḗҕ Semen Persicae) 20g, Bai Hua She 
She Cao (ⱑ㢅㲛㟠㤝 Herba Hedyotis Diffusae) 20g, 
San Leng (ϝễ Rhizoma Sparganii) 15g, E Zhu (㥾
ᴃ Rhizoma Curcumae) 15g, Wang Bu Liu Xing (⥟
ϡ⬭㸠 Semen Vaccariae) 15g, Shan Dou Gen (ቅ䈚
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ḍ Radix Sophorae Tonkinensis) 15g, Zhi Bie Jia (♌
努⬆ Carapax Trionycis Preparata) 15g, Zhi Chuan 
Shan Jia (♌こቅ⬆ Squama Manitis Preparata) 15g, 
Ba Qia (㦱㨰 Rhizoma Smilacis Chinensis) 15g, Ba 
Yue Zha (᳜ܿᴁ Fructus Akebiae) 15g and Jiao Shan 
Zha (⛺ቅ἖ charred Fructus Crataegi) 15g with a 
modification according to the patient’s condition, and 
among them 30 cases (76.4%) survived for over 3 
years, 21 cases for over 5 years and 5 cases for over 7 
years, indicating that the combined use of Chinese 
drugs and chemotherapy could obviously increase 
survival rate and noticeably decrease relapse and 
metastasis. The patients of nasopharyngeal carcinoma 
were treated with blood-activating and stasis- 
resolving formula consisting of Huang Qi (咘㡾
Radix Astragali), Chi Shao (䌸㡡 Radix Paeoniae 
Rubra), Tao Ren (ḗҕ Semen Persicae), Hong hua 
(㑶㢅 Flos Carthami), Chuan Xiong (Ꮁ㡢 Rhizoma 
Chuanxiong), Dang Gui (ᔧᔦ Radix Angelicae 
Sinensis), Ji XueTeng (叵㸔㮸Caulis Spatholobi), Ge 
Gen (㨯ḍ Radix Puerariae), Chen Pi (䰜Ⲃ
Pericarpium Citri Reticulatae) and Dan Shen (Ѝখ
Radix Salviae Miltiorrhizae) with a modification 
according to syndrome differentiation and radio- 
therapy, and the results showed that the treatment 
group treated with blood-activating and stasis- 
resolving formula and radiotherapy was significantly 
superior in rate of tumor subsiding and long-term 
survival rate to the control group treated with 
radiotherapy alone (P<0.05).13 This shows that 
combined use of BASRD and radiotherapy can 
strengthen therapeutic effect and inhibit relapse and 
metastasis of nasopharyngeal carcinoma. In a clinical 
trail on 20 cases of liver cancer treated with Hua Ji 
Dan (࣪⿃Ѝ mass-resolving pill) consisting of Nao 
Sha (⸛ⷖ Sal Purpureum), Ma Qian Zi (偀䪅ᄤ
Semen Strychni) and Gan Qi ( ᑆ ⓚ  Resina 
Toxicodendri) and Kang Liu Jian ( ᡫ ⯸ ✢
tumor-resisting decoction) consisting of Wu Shao She 
(РṶ㲛 Zaocys), Chen Pi (䰜Ⲃ Pericarpium Citri 
Reticulatae), Huang Qi (咘㡾 Radix Astragali), E Zhu 
(㥾ᴃ Rhizoma Curcumae), Zhu Ling (⣾㢧
Polyporus), Ban Xia (ञ໣ Rhizoma Pinelliae) and 
Tu Bie Chong (ೳ努㰿 Eupolyphaga seu Steleophaga) 
for activating blood and resolving mass with a 
modification according to the patient’s condition, 2 
cases survived for less than 6 months, 5 cases for 
6–12 months, 6 cases for 12–18 months, 3 cases for 
18–24 months, 2 cases for more than 5 years and 2 
cases for over 10 years, with an average survival rate 
of 19 months, and 1 case was cured, 6 cases were 
clinically cured, 5 cases relieved, 7 cases improved, 1 
case failed.14 22 cases of primary carcinoma of liver 
were treated by the method of soothing the liver and 
regulating qi, and activating blood and eliminating 
stasis with a formula consisting of Chai Hu (᷈㚵
Radix Bupleuri) 15g, Bai Zhu (ⱑᴃ Rhizoma 
Atractylodis Macrocephalae) 15g, San Leng (ϝễ
Rhizoma Sparganii) 30g, E Zhu (㥾ᴃ Rhizoma 
Curcumae) 30g, Dan Shen (Ѝখ Radix Salviae 
Miltiorrhizae) 30g, Ban Zhi Lian (ञᵱ㦆 Herba 
Scutellariae Barbatae) 30g, Zhu Ling ( ⣾ 㢧
Polyporus) 25g, Chen Pi (䰜Ⲃ Pericarpium Citri 
Reticulatae) 10g and Zhi Gan Cao (♭⫬㤝 Radix 
Glycyrrhizae Preparata) 5g with a modification 
according to the patient’s condition for 4 therapeutic 
courses (20 days as a course), and the results showed 
that 3 cases were relieved, 10 improved, and 9 failed 
with an improved rate of 45.45%.15 This indicates 
that the method can alleviate symptoms of primary 
liver cancer, reduce the sufferings and enhance living 
quality of patients.     
Chinese drugs for strengthening the body resistance 
and activating blood and resolving stasis can also be 
used to treat and prevent relapse and metastasis of 
cancer. 69 patients with gastric cancer at intermediate 
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or late stage were treated with a basic recipe for 
expelling cold with drugs of warm nature and 
resolving stasis, strengthening the spleen and 
stomach, eliminating toxin and resisting cancer,16
consisting of Huang Yao Zi (咘㥃ᄤ Rhizoma 
Dioscoreae Bulbiferae), Rou Gui (㙝Ḗ Cortex 
Cinnamomi), Gan Jiang (ᑆྰ Rhizoma Zingiberis ), 
Sheng Huang Qi (⫳咘㡾 Radix Astragali), Dang 
Shen (ܮখ Radix Codonopsis), Xu Duan (㓁ᮁ
Radix Dipsaci), Sha Yuan Zi (≭㢥ᄤ Semen 
Astragali Complanati), Chen Pi (䰜Ⲃ Pericarpium 
Citri Reticulatae), Zhe Shi (䍁⷇ Haematitum), Teng 
Li Gen (㮸ṼḍRadix Actinidiae Chinensis), Bai Hua 
She She Cao (ⱑ㢅㲛㟠㤝 Herba Hedyotis Diffusae), 
Bing Lang (ᾳὨ Semen Arecae), E Zhu (㥾ᴃ
Rhizoma Curcumae), Sheng Jiang (⫳ྰ Rhizoma 
Zingiberis Recens) and Da Zao (໻ᵷ Fructus 
Jujubae), and other 33 cases were treated with 
Chinese drugs and chemotherapy as the controls. 
85.4%, 84%, 56.4% and 45.4% of the patients in the 
treatment group survived for more than 0.5, over 1, 
over 3 and 5 years respectively with the average 
survival time at 2.45 years, whereas 83.3%, 76.7%, 
53.3%, 43.3% and 1.73 years in the control group 
respectively, indicating that the therapeutic effect in 
the treatment group was better than that in the control 
group. It follows that as compared to the chemo- 
therapy, Chinese medicine can particularly work on 
long-term survival time and living quality of patients 
with gastric cancer at intermediate or late stage. 
Jiawei Yiguan Jian (ࡴੇϔ䌃✢ Supplemented 
Ever-Effective Decoction) with the effects of 
nourishing yin and clearing away heat, and activating 
blood-and resolving stasis, consisting of Sha Shen 
(≭খ Radix Adenophorae), Mai Dong (呺ހ Radix 
Ophiopogonis), Gou Qi Zi (ᶌᴲᄤ Fructus Lycii), 
Long Kui (啭㩉Herba Solani Nigri), Jiang Can (ۉ㱩
Bombyx Batryticatus), Tu Bie Chong (ೳ努㰿
Eupolyphaga seu Steleophaga), Zhe Bei Mu (⌭䋱↡
Bulbus Fritillariae Thunbergii), Chuan Lian Zi (Ꮁἱ
ᄤ Fructus Toosendan), Wu Shao She (РṶ㲛Zaocys) 
and Wu Gong (㳜㱷 Scolopendra), was used to treat 
106 patients with lung cancer, of whom 50 cases of 
primary lung cancer missed operational opportunity 
or could not accept radiochemical therapy.7 The 
results of the treatment for 3–4 courses (4 weeks as a 
course) showed that 3 cases were completely 
alleviated, 21 cases partially alleviated, 36 cases were 
controlled and 46 cases were failed with a total 
effective rate of 56.6%. It was found in follow-up 
that 10 cases survived for 5–12 months, 18 for 1–2 
years, 19 for 2–3 years, 20 for 3–4 years, 13 for 4–5 
years, 6 for 6 years, 7 for 7 years, 4 for 8 years, 1 for 
9 years and 2 for 11 years, showing good effect on 
interior-heat due to yin deficiency, and deficiency of 
both qi and yin. It is reported that Qingyu Fuzheng 
Tang (⏙⯔ᡊℷ∸ decoction for removing blood 
stasis and strengthening body resistance) made of 
Huang Qi (咘㡾 Radix Astragali) 40g, Bai Shao (ⱑ
࣎ Radix Paeoniae Alba) 24g, Yan Hu Suo (ᓊ㚵㋶
Rhizoma Corydalis) 15g, Cao Guo (㤝ᵰ Fructus 
Tsaoko) 15g, Wu Zei Gu (Р䌐偼 Os Sepiae) 15g, Fu 
Ling (㤃㢧 Poria) 15g, Zhi Gan Cao (♭⫬㤝 Radix 
Glycyrrhizae Preparata) 15g, Duan Wa Leng Zi (✙⪺
ἲᄤ Concha Arcae Usta) 12g, Wu Ling Zi (Ѩ♉㛖
Faeces Trogopterorum) 10g, Mo Yao (≵㥃Myrrha) 
10g, Dang Gui (ᔧᔦ Radix Angelicae Sinensis) 10g, 
Bai Zhu (ⱑᴃ Rhizoma Atractylodis Macrocephalae) 
10g, Ji Nei Jin (叵ݙ䞥 Endothelium Corneum 
Gigeriae Galli) 10g, San Qi (ϝϗ Radix Notoginseng) 
15g (to be taken after being infused in the hot 
decoction) and Xi Yang Shen (㽓⋟খ Radix Panacis 
Quinquefolium) 10g was used to treat 60 patients of 
gastric cancer with syndrome of qi stagnation, blood 
stasis as well as deficiency of both qi and blood at 
intermediate or late stage.18 The patients were 
randomly divided into a treatment group treated with 
Chinese medicine for 3 months and a control group 
treated with chemotherapy for 3 cycles. The results 
showed that 2 cases were completely alleviated and 
12 cases partially alleviated with a total effective rate 
of 47.8% in the treatment group as compared to 
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43.3% in the control group, showing no significant 
difference. There were significant differences in 
living quality (P<0.01) and in body weight (P<0.05).  
It can be seen that in the treatment of gastric cancer at 
intermediate or late stage, Chinese medicine for 
activating blood and resolving stasis, nourishing qi
and blood, and softening and resolving hard mass can 
obviously enhance living quality of patients with 
remarkably better effect than that in chemotherapy.
Jiawei Zhi Po Liu Jun Tang (ࡴੇᶇᴈ݁৯∸
Supplemented Orange-Magnolia Six-Noble Dec- 
oction) made of Zhi Qiao (ᶇ໇ Fructus Aurantii), 
Hou Po (८ᴈCortex Magnoliae Officinalis), Bai Zhu 
(ⱑᴃRhizoma Atractylodis Macrocephalae), Fu Ling 
(㤃㢧 Poria), Chen Pi (䰜Ⲃ Pericarpium Citri 
Reticulatae), Ban Xia (ञ໣ Rhizoma Pinelliae), 
Dang Shen (ܮখ Radix Codonopsis Pilosulae), Wu 
Shao She (РṶ㲛 Zaocys), Wu Gong (㳜㱷
Scolopendra), Tu Bie Chong (ೳ努㰿 Eupolyphaga 
seu Steleophaga) and Gan Cao ( ⫬ 㤝 Radix 
Glycyrrhizae) for strengthening the spleen, removing 
blood stasis, dredging collaterals and resolving mass 
and Ping Xiao Pian (ᑇ⍜⠛Canelim Tablets)were 
used to treat 40 cases of gastric cancer with effective 
rate of 82.5%.19 Their living quality was enhanced in 
13 cases, stabilized in 23 cases and lowered in 4 
cases, and their body weight was increased in 12 
cases, stabilized in 24 cases and lowered in 4 cases, 
indicating the treatment can relieve clinical sym- 
ptoms and enhance living quality. Pain due to 
advanced esophagus cancer was treated with Yiqi 
Sanjie Tang (Ⲟ⇨ᬷ㒧∸ Decoction for nourishing qi
and resolving mass) made of Huang Qi (咘㡾 Radix 
Astragali) 20g, Gua Lou (⪰㩠 Fructus Trichosanthis) 
20g, Dang Shen (ܮখ Radix Codonopsis) 20g, Bai 
Zhu (ⱑᴃ Rhizoma Atractylodis Macrocephalae) 10g, 
Zhi Gan Cao (♭⫬㤝 Radix Glycyrrhizae Preparata) 
10g, Mu Xiang (᳼佭 Radix Aucklandiae) 10g, Dang 
Gui (ᔧᔦ Radix Angelicae Sinensis) 10g, Dan Shen 
(Ѝখ Radix Salviae Miltiorrhizae) 10g, Dong Ling 
Cao (ހޠ㤝 Herba Rabdosiae Rubescentis) 30g, Fu 
Ling (㤃㢧 Poria) 30g and Ban Zhi Lian (ञᵱ㦆
Herba Scutellariae Barbatae) 30g, plus Xiao Jie San 
(⍜㒧ᬷ Powder for resolving mass) consisting of 
Shui Zhi (∈㳁 Hirudo) 300g, Bi Hu (ຕ㰢 Gecko 
Domestica) 300g, San Qi (ϝϗ Radix Notoginseng) 
300g and Niu Huang (⠯咘 Calculus Bovis) 15g.20 32 
patients (40%) suffered from pain of Ċgrade and 48 
patients (60%) from pain of ċ grade before 
treatment. 0 grade pain took place in 68 patients 
(85%), ĉgrade pain in 8 patients (10%) and ċ grade 
pain in 4 patients (5%) after treatment with pain 
obviously reduced (P<0.05), indicating that the 
therapy has remarkable therapeutic effect on pain due 
to carcinoma of esophagus and can improve 
cytoimmunity and humoral immunity. It is reported 
that 52 cases of primary liver cancer were treated 
with Jiawei Zhi Po Liu Jun Tang (ࡴੇᶇᴈ݁৯∸
Supplemented Orange-Magnolia Six-Noble Dec- 
oction) made of Zhi Qiao (ᶇ໇ Fructus Aurantii) 15g, 
Hou Po (८ᴈ Cortex Magnoliae Officinalis) 15g, 
Dang Shen (ܮখ Radix Codonopsis) 15g, Bai Zhu 
(ⱑᴃ Rhizoma Atractylodis Macrocephalae) 15g, Fu 
Ling (㤃㢧 Poria) 15g, Ban Xia (ञ໣ Rhizoma 
Pinelliae) 15g, Chen Pi (䰜Ⲃ Pericarpium Citri 
Reticulatae) 15g, Wu Gong (㳜㱷 Scolopendra) 2 
pieces, Shui Zhi (∈㳁 Hirudo) 10g, Tu Bie Chong 
(ೳ努㰿 Eupolyphaga seu Steleophaga) 10g, Bai Tou 
Weng (ⱑ༈㖕 Radix Pulsatillae) 30g and Yi Yi Ren 
(㭣㢵ҕ Semen Coicis) 30g, 21 and Ai Di injection, 
Elemene injection, Brucea javanica fat emulsion 
injection and Kanglaite injection were infused 
respectively. 1–3 courses of treatment with one 
month as a course resulted in survival time less than 
6 months in 8 cases (15.3%), more than 6 months in 
10 cases (19.2 %), over 1 year in 25 cases (48.1%), 
over 2 years in 6 cases (11.5%) and over 3 years in 3 
cases (5.8%) with 1 year above survival rate of 
65.2%. It is reported that 36 gastric cancer patients 
after operation22  were treated with chemotherapy 
and a method for strengthening body resistance and 
removing blood stasis with a recipe consisting of 
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Huang Qi (咘㡾 Radix Astragali), Bie Jia (努⬆
Carapax Trionycis), She Liu Gu (㲛݁䈋 Rhizoma 
Amorphophalli), Bi Hu (ຕ㰢 Gecko Domestica),  
Bai Zhu (ⱑᴃ Rhizoma Atractylodis Macrocephalae), 
Yi Yi Ren (㭣㢵ҕ Semen Coicis), Dang Gui (ᔧᔦ
Radix Angelicae Sinensis), Fu Ling (㤃㢧 Poria) and 
Bai Hua She She Cao (ⱑ㢅㲛㟠㤝 Herba Hedyotis 
Diffusae). The treatment resulted in local metastasis 
and far-end transfer in 10 cases and no transfer or 
relapse in 22 cases in the treatment group as 
compared to 18 and 11 cases respectively in a control 
group of 32 cases treated with chemotherapy alone.  
Much less cases of metastasis in the treatment group 
than those in the control group confirms that the 
combined use of Chinese drugs for strengthening 
body resistance and removing blood stasis and 
chemotherapy can reduce far-end metastasis after 
operation for gastric cancer.  
2. Blood-activating and stasis-resolving method has 
dual effects of promoting and inhibiting adherence of 
tumor 
The view on preventing tumor metastasis with drugs 
for promoting blood circulation to remove blood 
stasis is challenged. In pharmacologically basic 
research, ZHANG Pei-tong and others23 have 
observed the influences of ligustrazine, hirudin, 
tanshinone ĊA and thrombase on invasion and 
adherence of a human highly metastatic giant lung 
carcinoma cell line PGCL3 and low metastasis lung 
cancer cell line PAa. The result has shown that 
ligustrazine, hirudin and thrombase can promote 
adherence of PGCL3 cells to different extent while 
tanshinone can inhibit their adherence. Ligustrazine, 
hirudin and tanshinone ĊA can inhibit invasion of 
Boyden chamber by PGCL3 cells and inhibit the 
action of platelet in synergy with invasion by PGCL3 
and PAa cells, while thrombase can obviously 
promote those processes. It can thus be seen that 
blood-activating drugs may have dual effects of 
promoting and inhibiting invasion and metastasis of 
tumor cells. It is reported that Dan Shen (Ѝখ Radix 
Salviae Miltiorrhizae) can promote hematogenous 
dissemination and metastasis of cancer cells in 
experimental rats. It was clinically confirmed that 
tissue plasminogen activator of plasma in the patients 
with some malignant cancers of blood stasis 
syndrome was over 1 time more active than that in 
control group, but there was no obvious difference in 
tissue plasminogen inhibitor. Obviously enhanced 
activity of tissue plasminogen activator, hyper- 
fibrinolysis and lowered blood viscosity can promote 
local infiltration of malignant tumor and its transfer 
to the whole body. Therefore, blood-activating and 
stasis-resolving method should be used with caution 
and the principle of simultaneously supporting the 
health and eliminating the evil should be adopted in 
treatment of malignant tumor. 
3. BASRD should be reasonably used at appropriate 
time 
In treating malignant tumor by BASRD, it is 
important to grasp their ingredients and proportion in 
the prescription and select the drugs for obtaining
better therapeutic effect and avoiding deterioration of 
patient’s condition and deteriorated syndrome.           
Proper dosage and potency of BASRD should be 
used to treat cancer belonging to different syndromes 
and at different stages. In using a recipe for 
nourishing qi and generating blood to treat gastric 
cancer of qi and blood deficiency, analysis of 
relationship between the intensity of BASRD and 
metastatic rate of gastric cancer has shown that the 
metastatic rate of gastric cancer of qi and blood 
deficiency increases with the increase in proportion 
of BASRD. 24 It can thus be seen that when quantity 
and aggregation of blood plantlet obviously reduce, 
clotting time is remarkably prolonged and fibri- 
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nolysate increases in patients with gastric cancer of qi
and blood deficiency, the proportion of BASRD in 
the recipe should be decreased to avoid tumor 
transfer. When drugs for strengthening the body 
resistance and BASRD are used together to treat 
cancer patients with deficiency of qi, blood, yin and 
yang, the dosage and proportion of drugs for 
strengthening the body resistance should be increased.  
Research into precancerosis of atrophic gastritis25 has 
shown that vascular distortion, thickened vascular 
wall, narrowed vascular cavity, “piebald change” and 
“papuloid change” in gastric mucosa discovered 
under gastroscope belong to blood stasis syndrome.  
Gland atrophy, atypical hyperplasia and extent of 
intestinalization in blood stasis syndrome are severer 
than those in other syndromes. Qi and blood should 
be emphatically regulated, attention should be paid to 
strengthening the use of blood-activating drugs, and 
the dosage of BASRD should be increased in order to 
improve local microcirculation of focus in gastric 
mucosa, eliminate or alleviate the infiltration of 
inflammatory cells, promote the recovery of atrophic 
gland and prevent intestinalization and abnormal 
hyperplasia of cells. 
The dose and time of administration BASRD should 
be grasped in treating malignant tumor with Chinese
and Western medicine. In studying the treatment of 
non-small cell lung cancer with Chinese and Western 
medicine, WANG Bing-sheng and others26 put 
forward that BASRD have different influence before 
and after chemotherapy. After bronchial artery 
perfusion chemotherapy for 3–5 days, the drugs for 
nourishing qi and activating blood and drugs for 
nourishing qi, activating blood and resolving mass 
were administered respectively. In the first 6 months 
of chemotherapy, rate of tumor metastasis was 7.4% 
and 26.7% respectively. No significant difference was 
found between the 2 groups from 6 months to 2 years.  
The mean survival time was 16.1 and 13.8 months 
respectively. Long-term survival rate in 1, 1.5 and 2 
years was 85.1%, 67.7% and 61.1% respectively in 
one group and 36.6%, 22.2% and 10% respectively in 
the other group with significant difference in 1-year 
survival rate between the 2 groups (P<0.05).  
During short-term chemotherapy, the therapeutic 
effect of drugs for replenishing qi and activating 
blood is better than that of drugs for resolving mass 
and removing blood stasis, and the latter can not 
enhance short-term therapeutic effect. After 
long-term chemotherapy, no difference is found 
between the two groups. The reason why during 
short-term chemotherapy, taking drugs for resolving 
mass and removing blood stasis possibly promotes 
metastasis may be that a large amount of chemo- 
therapeutic drugs accumulated in the body impair 
vital qi, lower immunity and weaken ability of the 
body to inhibit proliferation of cancer cells. At that 
time, the additional use of drugs for resolving mass 
and removing blood stasis makes it easy to some 
extent for cancer cells to reach other sites, forming 
metastatic focus after a period of time. It can thus be 
seen that at the early stage of chemotherapy, using 
drugs for nourishing qi and promoting blood 
circulation can not only strengthen immunity and 
reduce the rate of cancer foci metastasis but also 
enhance long-term survival rate. After the focus has 
been stabilized, it is a good method to use drugs for 
strengthening the body resistance and eliminating 
pathogenic factors and to additionally use drugs for 
resolving mass and blood stasis.   
To sum up, in clinical treatment of tumor, BASRD 
should not be used alone but used in combination 
with deficiency-supplementing drugs for replenishing 
qi, assisting yang and nourishing yin to make it 
uneasy for tumor cells to shed off nor adhere to far 
end.  
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